Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RCUS |
---|---|---|
09:32 ET | 5969 | 15.16 |
09:38 ET | 100 | 15.03 |
09:39 ET | 802 | 15.13 |
09:41 ET | 2893 | 15.18 |
09:43 ET | 100 | 15.12 |
09:45 ET | 1490 | 15.17 |
09:48 ET | 100 | 15.17 |
09:50 ET | 200 | 15.11 |
09:52 ET | 1739 | 15.13 |
09:54 ET | 1382 | 15.19 |
09:56 ET | 1000 | 15.25 |
09:57 ET | 1140 | 15.2 |
09:59 ET | 600 | 15.23 |
10:01 ET | 2047 | 15.19 |
10:03 ET | 600 | 15.185 |
10:06 ET | 900 | 15.14 |
10:08 ET | 5270 | 15.135 |
10:10 ET | 1691 | 15.125 |
10:12 ET | 8581 | 15.01 |
10:14 ET | 2000 | 15.04 |
10:15 ET | 1348 | 14.9 |
10:17 ET | 300 | 14.9 |
10:19 ET | 300 | 14.9 |
10:21 ET | 800 | 15 |
10:24 ET | 500 | 15.03 |
10:28 ET | 100 | 15.045 |
10:30 ET | 200 | 15.02 |
10:33 ET | 4149 | 15.066 |
10:35 ET | 300 | 15.11 |
10:37 ET | 100 | 15.09 |
10:39 ET | 700 | 15.065 |
10:42 ET | 100 | 15.05 |
10:44 ET | 238 | 15.02 |
10:46 ET | 607 | 15.01 |
10:48 ET | 300 | 14.98 |
10:50 ET | 160 | 15.01 |
10:51 ET | 200 | 15.015 |
10:53 ET | 376 | 15.015 |
10:55 ET | 633 | 15.02 |
10:57 ET | 100 | 15 |
11:00 ET | 795 | 15.035 |
11:04 ET | 1913 | 14.985 |
11:06 ET | 337 | 14.95 |
11:08 ET | 100 | 14.92 |
11:09 ET | 699 | 14.93 |
11:11 ET | 100 | 14.93 |
11:13 ET | 1305 | 14.93 |
11:18 ET | 500 | 14.88 |
11:20 ET | 300 | 14.86 |
11:22 ET | 100 | 14.83 |
11:24 ET | 200 | 14.84 |
11:26 ET | 2962 | 14.855 |
11:27 ET | 100 | 14.84 |
11:29 ET | 596 | 14.81 |
11:31 ET | 2215 | 14.79 |
11:33 ET | 1330 | 14.775 |
11:36 ET | 700 | 14.76 |
11:38 ET | 200 | 14.76 |
11:42 ET | 440 | 14.76 |
11:44 ET | 1700 | 14.75 |
11:45 ET | 300 | 14.76 |
11:47 ET | 888 | 14.77 |
11:49 ET | 830 | 14.74 |
11:54 ET | 1800 | 14.69 |
11:56 ET | 2449 | 14.66 |
11:58 ET | 400 | 14.67 |
12:00 ET | 2838 | 14.62 |
12:02 ET | 400 | 14.62 |
12:03 ET | 1659 | 14.52 |
12:05 ET | 1075 | 14.545 |
12:07 ET | 400 | 14.54 |
12:09 ET | 4253 | 14.58 |
12:12 ET | 325 | 14.575 |
12:14 ET | 1350 | 14.525 |
12:16 ET | 1267 | 14.49 |
12:18 ET | 461 | 14.485 |
12:20 ET | 836 | 14.47 |
12:21 ET | 1261 | 14.46 |
12:23 ET | 1392 | 14.455 |
12:25 ET | 400 | 14.455 |
12:27 ET | 513 | 14.455 |
12:30 ET | 1238 | 14.43 |
12:32 ET | 200 | 14.445 |
12:34 ET | 2719 | 14.47 |
12:36 ET | 400 | 14.46 |
12:38 ET | 1100 | 14.425 |
12:39 ET | 342 | 14.425 |
12:41 ET | 685 | 14.405 |
12:43 ET | 817 | 14.355 |
12:45 ET | 283 | 14.355 |
12:48 ET | 304 | 14.355 |
12:50 ET | 1400 | 14.345 |
12:52 ET | 420 | 14.31 |
12:54 ET | 216 | 14.325 |
12:56 ET | 528 | 14.3 |
12:57 ET | 804 | 14.29 |
12:59 ET | 1872 | 14.31 |
01:01 ET | 478 | 14.285 |
01:03 ET | 6343 | 14.32 |
01:06 ET | 3214 | 14.34 |
01:08 ET | 6251 | 14.37 |
01:10 ET | 1300 | 14.4 |
01:12 ET | 800 | 14.36 |
01:14 ET | 500 | 14.385 |
01:15 ET | 900 | 14.4075 |
01:17 ET | 500 | 14.42 |
01:19 ET | 7689 | 14.49 |
01:21 ET | 1508 | 14.51 |
01:24 ET | 1289 | 14.53 |
01:26 ET | 1300 | 14.51 |
01:28 ET | 2252 | 14.54 |
01:30 ET | 910 | 14.515 |
01:32 ET | 530 | 14.49 |
01:33 ET | 1012 | 14.51 |
01:35 ET | 800 | 14.51 |
01:37 ET | 1330 | 14.51 |
01:39 ET | 1440 | 14.53 |
01:42 ET | 1018 | 14.5 |
01:44 ET | 300 | 14.48 |
01:46 ET | 1537 | 14.485 |
01:48 ET | 1276 | 14.475 |
01:50 ET | 1657 | 14.51 |
01:51 ET | 1346 | 14.53 |
01:53 ET | 500 | 14.54 |
01:55 ET | 200 | 14.55 |
01:57 ET | 728 | 14.535 |
02:00 ET | 1331 | 14.53 |
02:02 ET | 646 | 14.54 |
02:04 ET | 650 | 14.54 |
02:06 ET | 572 | 14.54 |
02:08 ET | 458 | 14.52 |
02:09 ET | 838 | 14.53 |
02:11 ET | 1405 | 14.505 |
02:13 ET | 300 | 14.49 |
02:15 ET | 800 | 14.49 |
02:18 ET | 1471 | 14.47 |
02:20 ET | 602 | 14.475 |
02:22 ET | 3050 | 14.46 |
02:24 ET | 1000 | 14.47 |
02:26 ET | 7503 | 14.56 |
02:27 ET | 600 | 14.56 |
02:29 ET | 300 | 14.57 |
02:31 ET | 1356 | 14.59 |
02:33 ET | 1016 | 14.56 |
02:36 ET | 300 | 14.54 |
02:38 ET | 600 | 14.555 |
02:40 ET | 200 | 14.555 |
02:42 ET | 200 | 14.57 |
02:44 ET | 783 | 14.5275 |
02:45 ET | 600 | 14.54 |
02:47 ET | 300 | 14.525 |
02:49 ET | 5426 | 14.5 |
02:51 ET | 5225 | 14.42 |
02:54 ET | 1445 | 14.4 |
02:56 ET | 6792 | 14.43 |
02:58 ET | 3011 | 14.4728 |
03:00 ET | 643 | 14.5 |
03:02 ET | 510 | 14.46 |
03:03 ET | 1348 | 14.5 |
03:05 ET | 1800 | 14.45 |
03:07 ET | 1953 | 14.45 |
03:09 ET | 2664 | 14.5 |
03:12 ET | 300 | 14.52 |
03:14 ET | 1063 | 14.44 |
03:16 ET | 700 | 14.41 |
03:18 ET | 700 | 14.43 |
03:20 ET | 3825 | 14.5 |
03:21 ET | 376 | 14.5 |
03:23 ET | 999 | 14.53 |
03:25 ET | 3465 | 14.51 |
03:27 ET | 803 | 14.5 |
03:30 ET | 1913 | 14.51 |
03:32 ET | 3930 | 14.49 |
03:34 ET | 301 | 14.47 |
03:36 ET | 509 | 14.44 |
03:38 ET | 1188 | 14.43 |
03:39 ET | 2802 | 14.41 |
03:41 ET | 800 | 14.405 |
03:43 ET | 600 | 14.4 |
03:45 ET | 12231 | 14.455 |
03:48 ET | 5076 | 14.46 |
03:50 ET | 25760 | 14.47 |
03:52 ET | 15312 | 14.54 |
03:54 ET | 11638 | 14.61 |
03:56 ET | 13538 | 14.565 |
03:57 ET | 21815 | 14.63 |
03:59 ET | 77161 | 14.65 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Arcus Biosciences Inc | 1.3B | -4.7x | --- |
Ardelyx Inc | 1.2B | -18.3x | --- |
Gyre Therapeutics Inc | 1.0B | -6.4x | --- |
Vir Biotechnology Inc | 1.2B | -2.2x | --- |
Immatics NV | 1.2B | -11.5x | --- |
Prothena Corporation PLC | 1.1B | -6.3x | --- |
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
---|---|
Revenue (TTM) | $237.0M |
Shares Outstanding | 91.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.90 |
EPS | $-3.10 |
Book Value | $6.12 |
P/E Ratio | -4.7x |
Price/Sales (TTM) | 5.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -113.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.